Marksans Pharma Ltd Stock Price Today (NSE: MARKSANS)
Fundamental Score
Marksans Pharma Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Marksans Pharma Ltd share price today is ₹176.61, up +0.00% on NSE/BSE as of 20 February 2026. Marksans Pharma Ltd (MARKSANS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹8.82K (Cr). The 52-week high for MARKSANS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 25.09x, MARKSANS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.77% and a debt-to-equity ratio of 0.12.
Marksans Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Marksans Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Marksans Pharma Share Price: A Conservative Value Investor's Perspective
One unique aspect of the pharmaceutical industry is its inherent resilience due to consistent demand for healthcare products. Even during economic downturns, essential medications and treatments remain necessary, providing a degree of stability. This analysis examines the Marksans Pharma share price from a conservative value investing standpoint, prioritizing capital safety and long-term sustainability. The current price stands at ₹177.360001, with a Price-to-Earnings (PE) ratio of 25.09 and a Return on Capital Employed (ROCE) of 20.03%.
Marksans Pharma's ROCE of 20.03% is a key metric. A high ROCE signifies efficient capital allocation and suggests a potential economic moat. It indicates that the company is generating significant returns on its invested capital, which can be reinvested for future growth or returned to shareholders. Sustained high ROCE over time can strengthen the company's competitive advantage, making it more difficult for competitors to erode its profitability.
While a quantitative analysis is crucial, qualitative aspects are equally important. When compared to a peer like
Mankind Pharma Ltd, assessing management quality becomes paramount. A strong management team can navigate industry challenges, make sound strategic decisions, and ultimately create shareholder value. Factors like capital allocation acumen, ethical governance, and a track record of delivering consistent results are vital considerations.Finally, it's crucial to note that this analysis is part of a broader, 80-parameter fundamental audit verified by Sweta Mishra. This in-depth evaluation focuses on various aspects of Marksans Pharma's financial health, including its balance sheet strength, cash flow generation, and debt levels. The analysis relies on observational data and publicly available information; it does not constitute financial advice or a recommendation to buy or sell Marksans Pharma shares. All investment decisions should be made after consulting with a qualified financial advisor and conducting thorough due diligence.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Marksans Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MARKSANS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.03%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.23%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 25.09 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (18.25% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.25% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.78% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.12)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (27.07x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹427.21 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Marksans Pharma Ltd Financial Statements
Comprehensive financial data for Marksans Pharma Ltd including income statement, balance sheet and cash flow
About MARKSANS (Marksans Pharma Ltd)
Marksans Pharma Ltd (MARKSANS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹8.82K (Cr). Marksans Pharma Ltd has delivered a Return on Equity (ROE) of 16.77% and a ROCE of 20.03%. The debt-to-equity ratio stands at 0.12, reflecting the company's capital structure. Investors tracking MARKSANS share price can monitor key metrics including P/E ratio, promoter holding of 43.87%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
MARKSANS Share Price: Frequently Asked Questions
What is the current share price of Marksans Pharma Ltd (MARKSANS)?
As of 20 Feb 2026, 06:17 am IST, Marksans Pharma Ltd share price is ₹176.61. The MARKSANS stock has a market capitalisation of ₹8.82K (Cr) on NSE/BSE.
Is MARKSANS share price Overvalued or Undervalued?
MARKSANS share price is currently trading at a P/E ratio of 25.09x, compared to the industry average of 31.77x. Based on this relative valuation, the Marksans Pharma Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of MARKSANS share price?
The 52-week high of MARKSANS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Marksans Pharma Ltd share price?
Key factors influencing MARKSANS share price include quarterly earnings growth (Sales Growth: 12.23%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Marksans Pharma Ltd a good stock for long-term investment?
Marksans Pharma Ltd shows a 5-year Profit Growth of 25.78% and an ROE of 16.77%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.12 before investing in MARKSANS shares.
How does Marksans Pharma Ltd compare with its industry peers?
Marksans Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare MARKSANS share price P/E of 25.09x and ROE of 16.77% against the industry averages to determine competitive standing.
What is the P/E ratio of MARKSANS and what does it mean?
MARKSANS share price has a P/E ratio of 25.09x compared to the industry average of 31.77x. Investors pay ₹25 for every ₹1 of annual earnings.
How is MARKSANS performing according to Bull Run's analysis?
MARKSANS has a Bull Run fundamental score of 64/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MARKSANS belong to?
MARKSANS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Marksans Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for MARKSANS?
MARKSANS has an ROE of 16.77%, which indicates excellent management efficiency. ROE measures how efficiently Marksans Pharma Ltd generates profits from shareholders capital.
How is MARKSANS debt-to-equity ratio and what does it indicate?
MARKSANS has a debt-to-equity ratio of 0.12, which indicates conservative financing with low financial risk.
What is MARKSANS dividend yield and is it a good dividend stock?
MARKSANS offers a dividend yield of 0.41%, meaning you receive ₹0.41 annual dividend for every ₹100 invested in Marksans Pharma Ltd shares.
How has MARKSANS share price grown over the past 5 years?
MARKSANS has achieved 5-year growth rates of: Sales Growth 18.25%, Profit Growth 25.78%, and EPS Growth 23.25%.
What is the promoter holding in MARKSANS and why does it matter?
Promoters hold 43.87% of MARKSANS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Marksans Pharma Ltd.
What is MARKSANS market capitalisation category?
MARKSANS has a market capitalisation of ₹8823 crores, placing it in the Mid-cap category.
How volatile is MARKSANS stock?
MARKSANS has a beta of N/A. A beta > 1 suggests the Marksans Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MARKSANS operating profit margin trend?
MARKSANS has a 5-year average Operating Profit Margin (OPM) of 20.23%, indicating the company's operational efficiency.
How is MARKSANS quarterly performance?
Recent quarterly performance shows Marksans Pharma Ltd YoY Sales Growth of 12.23% and YoY Profit Growth of 1.58%.
What is the institutional holding pattern in MARKSANS?
MARKSANS has FII holding of 16.92% and DII holding of 5.28%. Significant institutional holding often suggests professional confidence in the Marksans Pharma Ltd stock.